Biologically adaptive radiotherapy for oropharyngeal cancer

Not Applicable

• Conditions: Oropharyngeal cancer, stage III/IVa/IVb; Cancer

• Registration Number: ISRCTN45653542
• Lead Sponsor: HS Greater Glasgow and Clyde

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-02
• Last Update Posted: 25 March 2024
• Study Completion: 2026-03-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Histologically confirmed HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) or HPV-positive OPSCC and significant smoking history (>20 pack years) within the past 20 years
2. Stage III, IVa or IVb OPSCC
3. Scheduled for single modality photon radiotherapy as primary radical treatment
4.18 years old and over
5. Able to give informed consent
6. Patients willing and able to comply with the protocol for the duration of the study

Exclusion Criteria

1. Head and neck cancers from sub-sites other than oropharynx
2. HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) in patients with no significant smoking history (low-risk OPSCC)
3. Confirmed distal metastatic disease (stage IVc)
4. Patients who have undergone primary surgery for OPSCC (including neck dissection)
5. Patients who have received induction chemotherapy prior to definitive treatment
6. Patients receiving chemoradiotherapy or cetuximab-radiotherapy
7. Prior radiotherapy to the head and neck region
8. Patients with contra-indications to MRI scanning
9. Patients who do not adequately understand verbal or written information

Study & Design

• Study Type: Interventional
• Study Design: Not specified